You’ve probably heard the news by now that German drug maker Merck has allegedly developed an experimental COVID-19 pill that can cut the risk of hospitalization and death in half. The name of Merck’s new drug is Molnupiravir, and the results of their studies on it have not been peer reviewed. What some people find strange about the situation ties into Merck’s other drug Ivermectin, which also allegedly does the same thing as their new pill, and is used in some countries as treatment.
Did Merck Publicly Smear Ivermectin to Make Way for Their New Drug Molnupiravir?
Merck has stopped clinical trials of their Molnupiravir on grounds that the results are so profound that it should be authorized for emergency use. According to results of their studies around 7% of people who took Molnupiravir were hospitalized or died from COVID, compared to 14% who took a placebo.
What’s strange to some people is that Merck publicly smeared their own Ivermectin pill despite it allegedly showing similar levels of effectiveness in people who took it after being infected with COVID-19. Some people believe Merck was smear campaigning their own drugs, because they were in development of a new more expensive drug that had no generic versions, and new patent.
Here is what Merck said in a past statement regarding their Ivermectin drug for use as COVID-19 treatment,
- It has No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies;
- It has No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and;
- It has a concerning lack of safety data in the majority of studies.
Conspiracy theorists believe Merck was supporting the public smear campaign of Ivermectin, because it would have interfered with the need of their new Molnupiravir pill with a new patent.
The Cost of Merck’s Ivermectin vs Merck’s Molnupiravir Antiviral Pill
At the moment you can get the generic version of Merck’s Ivermectin for around $45 for a box of eight pills, or $79 for a box of 20 pills. If you do that math that’s around $4 to $7 per pill. On the flipside the US government has made an advanced purchase of 1.7 million doses of Merck’s Molnupiravir drug for around $1.2 Billion. If you do the math that’s around $700 per dose of Molnupiravir.
It’s easy to see Molnupiravir brings Merck way more profit than Ivermectin. Could that really be the reason Merck publicly smeared its own drug Ivermectin for COVID treatment? For most large companies money is always the motive.
Author: JordanThrilla Staff